aberrant behavior checklist irritability subscale

Aripiprazole in pervasive developmental disorder not otherwise.

aberrant behavior checklist irritability subscale

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to.

RUPP Risperidone study - CAIRN | Canadian Autism Intervention.

Though increasingly sophisticated educational programs and behavior therapy. of treatment: the irritability subscale of the Aberrant Behavior Checklist and the.
BMS — Adolescent and School-Age Psychiatric Intervention.
Clinical Global Impressions-Improvement [ Time Frame: Weekly ] [ Designated as safety issue: No ]; Aberrant Behavior Checklist-Irritability subscale [ Time.
The effect size d was 1.2 in favor of risperidone on the main outcome measure, the Irritability subscale of the Aberrant Behavior Checklist (ABC) (Aman et al.

NCT00549562 - ClinicalTrials.gov.
Dec 1, 2007. Fewer aberrant behaviors were recorded for febrile patients on the Aberrant Behavior Checklist subscales of irritability, hyperactivity, stereotypy.

Dec 1, 2007. Fewer aberrant behaviors were recorded for febrile patients on the Aberrant Behavior Checklist subscales of irritability, hyperactivity, stereotypy.

Primary Outcome Measures: The Irritability subscale of the Aberrant Behavior Checklist (ABC) will be used as the caregiver-rated primary outcome measure.
Feb 1, 2005. See Table 3 for details of the ABC-C irritability subscale questions... Aberrant Behavior Checklist Community Scale Irritability Subscale Itemsa.
Primary outcome measures were the Aberrant Behavior Checklist irritability subscale and the Clinical Global Impression improvement scale. RESULTS: Part I.
The primary efficacy measure was the Aberrant Behavior Checklist-Irritability ( ABC-I) subscale. Data were available for 55 children given risperidone (n=27) or .